Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK

Next Previous
Search
Trial Profile

3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anatabine (Primary)
  • Indications Alzheimer's disease; Inflammation; Multiple sclerosis; Neurological disorders
  • Focus Pharmacokinetics
  • Sponsors Rock Creek Pharmaceuticals Inc

    • Most Recent Events

    • 03 Feb 2016 Interim report of the pharmacodynamic results of this trial published in a Rock Creek Pharmaceuticals media release.s
    • 19 Oct 2015 Status changed from active, no longer recruiting to completed according to a Rock Creek Pharmaceuticals media release.
    • 10 Aug 2015 According to a Rock Creek Pharmaceuticals Inc. media release, part two of this study will be conducted with a protocol amendment that primarily evaluates the effects of food on PK parameters. The dosing for part two is expected to commence and be completed within the third quarter of 2015. amendment. Part three is expected to be complete along with prelimnary results in the third quarter of 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top